Takeda, Baxter expand vax collaboration; J&J offers $2.3B for Crucell;

Vaccine Research 

> Takeda and Baxter "will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market." Report

> The FDA has given Bavarian Nordic the green light to launch a late stage trial of its prostate cancer vaccine. Story

> In a research report presented in the December 2010 issue of the Journal of Leukocyte Biology, scientists from Singapore show that Mycobacterium chelonae, a common environmental bacterium found in soil and water, can decrease the effectiveness of the bacille Calmette-Guerin (BCG) vaccine used to prevent tuberculosis, especially in countries outside of the United States. Release

Vaccine Market

> J&J has formally offered $2.3 billion to acquire the Dutch vaccine maker Crucell. The two companies agreed on the buyout last October. If the deal proceeds as planned, J&J's vaccine gambit will qualify as its biggest acquisition in four years. Article

> Canadian health officials are calling for a national vaccination strategy, saying it's time to do away with the "patchwork" approach that has been in use. Story

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.